531.67

0.84% 4.45

After Hours: 532.00 0.33 +0.06%

Thermo Fisher Scientific Inc (TMO)

Overview News Price History Option Chain Financials Why TMO Down? Discussions Forecast Stock Split Dividend History

Thermo Fisher Scientific Inc stock is traded at $531.67, with a volume of 2.00M. It is up +0.84% in the last 24 hours and up +14.49% over the past month. Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Previous Close:

$527.22

Open:

$528.88

24h Volume:

2.00M

Relative Volume:

0.87

Market Cap:

$197.58B

Revenue:

$44.56B

Net Income/Loss:

$6.72B

P/E Ratio:

29.97

EPS:

17.7387

Net Cash Flow:

$6.29B

1W Performance:

+5.60%

1M Performance:

+14.49%

6M Performance:

+0.72%

1Y Performance:

+20.56%

1-Day Range:

$524.76

$532.86

1-Week Range:

$490.25

$532.86

52-Week Range:

$385.46

$643.99

Thermo Fisher Scientific Inc Stock (TMO) Company Profile

Name

Thermo Fisher Scientific Inc

Sector

Healthcare (1112)

Industry

Diagnostics & Research (52)

Phone

(781) 622-1000

Address

168 THIRD AVENUE, WALTHAM, MA

Employee

125,000

Twitter

@thermofisher

Next Earnings Date

2026-04-23

Latest SEC Filings

TMO's Discussions on Twitter

Compare TMO vs DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TMO Thermo Fisher Scientific Inc	531.67	195.93B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	198.14	140.56B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	580.76	46.39B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	119.77	34.02B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	326.20	32.49B	3.17B	642.63M	516.49M	10.77

Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	DZ Bank	Buy
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Dec-09-25	Initiated	Goldman	Buy
Dec-08-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Dec-02-25	Resumed	Morgan Stanley	Overweight
Dec-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-11-25	Upgrade	Barclays	Equal Weight → Overweight
Aug-19-25	Initiated	William Blair	Outperform
Jul-24-25	Downgrade	HSBC Securities	Buy → Hold
Jul-11-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jul-09-25	Downgrade	UBS	Buy → Neutral
Jan-10-25	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-23-24	Initiated	Scotiabank	Sector Perform
Oct-14-24	Initiated	Redburn Atlantic	Buy
Oct-01-24	Initiated	Stephens	Overweight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-03-24	Resumed	Jefferies	Buy
Mar-18-24	Resumed	Citigroup	Neutral
Jan-24-24	Downgrade	Barclays	Overweight → Equal Weight
Jan-08-24	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-18-23	Initiated	HSBC Securities	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-26-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-25-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Sep-28-23	Initiated	Bernstein	Outperform
Sep-06-23	Resumed	Citigroup	Buy
Jul-19-23	Initiated	Raymond James	Outperform
Jul-19-23	Reiterated	Robert W. Baird	Outperform
Jul-13-23	Upgrade	Credit Suisse	Neutral → Outperform
Apr-04-23	Reiterated	Barclays	Overweight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-27-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Neutral
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Jan-26-22	Resumed	Barclays	Overweight
Oct-20-21	Upgrade	Citigroup	Neutral → Buy
Oct-15-21	Resumed	Cowen	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-16-21	Initiated	The Benchmark Company	Buy
Mar-18-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-03-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Neutral → Outperform
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Initiated	Goldman	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Sep-14-20	Initiated	Morgan Stanley	Overweight
Aug-20-20	Resumed	JP Morgan	Overweight
Jul-15-20	Upgrade	Cleveland Research	Neutral → Buy
Jul-07-20	Reiterated	Needham	Buy
Apr-23-20	Reiterated	Needham	Buy
Jan-31-20	Reiterated	Needham	Buy
Jan-22-20	Initiated	Credit Suisse	Neutral
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Buy
Nov-15-19	Initiated	Stifel	Buy
Jul-25-19	Reiterated	Needham	Buy
Jul-16-19	Downgrade	Needham	Strong Buy → Buy
May-30-19	Initiated	Wolfe Research	Outperform
May-23-19	Reiterated	Needham	Strong Buy
Apr-22-19	Reiterated	Needham	Strong Buy
Apr-16-19	Reiterated	BofA/Merrill	Buy

View All

Thermo Fisher Scientific Inc Stock (TMO) Latest News

Apr 14, 2026

Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch

Apr 14, 2026

Thermo Fisher Scientific and PRECISE Partner on Singapore Proteomics Study - Clinical Lab Products

Apr 14, 2026

Barclays Adjusts Price Target on Thermo Fisher Scientific to $625 From $650, Maintains Overweight Rating - marketscreener.com

Apr 14, 2026

A Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Volatility - Yahoo Finance

Apr 14, 2026

Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities - BioSpace

Apr 14, 2026

Apr 13, 2026